<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font18 { font-size : 18; } .font22 { font-size : 22; } .font24 { font-size : 24; } .font10 { font-size : 10; } .font27 { font-size : 27; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font27">the </span>
   <span class="font24">for </span>
   <span class="font22">with </span>
   <span class="font18">hepatitis </span>
   <span class="font15">HBV </span>
   <span class="font14">chronic </span>
   <span class="font14">treatment </span>
   <span class="font14">viral </span>
   <span class="font14">HCV </span>
   <span class="font14">virus </span>
   <span class="font14">patients </span>
   <span class="font13">al. </span>
   <span class="font13">cirrhosis </span>
   <span class="font13">liver </span>
   <span class="font12">has </span>
   <span class="font12">infection </span>
   <span class="font12">{background </span>
   <span class="font12">disease </span>
   <span class="font12">antiviral </span>
   <span class="font12">are </span>
   <span class="font12">from </span>
   <span class="font12">have </span>
   <span class="font12">DNA </span>
   <span class="font12">margin </span>
   <span class="font12">those </span>
   <span class="font11">who </span>
   <span class="font11">{border-style </span>
   <span class="font11">United </span>
   <span class="font11">been </span>
   <span class="font11">not </span>
   <span class="font11">will </span>
   <span class="font11">px;} </span>
   <span class="font11">risk </span>
   <span class="font11">screening </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">Hepatitis </span>
   <span class="font11">prevalence </span>
   <span class="font11">that </span>
   <span class="font11">after </span>
   <span class="font11">all </span>
   <span class="font11">associated </span>
   <span class="font11">decompensated </span>
   <span class="font11">including </span>
   <span class="font11">renal </span>
   <span class="font11">care </span>
   <span class="font11">collab: </span>
   <span class="font11">recent </span>
   <span class="font11">therapies </span>
   <span class="font11">ALT </span>
   <span class="font11">burden </span>
   <span class="font11">management </span>
   <span class="font11">may </span>
   <span class="font11">population </span>
   <span class="font11">recommendations </span>
   <span class="font11">Hepatology;:‐. </span>
   <span class="font11">drug </span>
   <span class="font11">virologic </span>
   <span class="font11">&amp;gt; </span>
   <span class="font11">HDV </span>
   <span class="font11">Health </span>
   <span class="font11">Hepatol;:‐. </span>
   <span class="font11">TAF </span>
   <span class="font11">World </span>
   <span class="font11">cure </span>
   <span class="font11">infection, </span>
   <span class="font11">infection. </span>
   <span class="font11">patient </span>
   <span class="font11">populations </span>
   <span class="font11">these </span>
   <span class="font11">this </span>
   <span class="font11">transplant </span>
   <span class="font11">with/without </span>
   <span class="font11">without </span>
   <span class="font11">years </span>
   <span class="font10">Additionally, </span>
   <span class="font10">Chronic </span>
   <span class="font10">DAA </span>
   <span class="font10">HBsAg </span>
   <span class="font10">However, </span>
   <span class="font10">Liver </span>
   <span class="font10">TDF </span>
   <span class="font10">The </span>
   <span class="font10">Treatment </span>
   <span class="font10">development </span>
   <span class="font10">most </span>
   <span class="font10">strategies </span>
   <span class="font10">tenofovir </span>
   <span class="font10">testing </span>
   <span class="font10">therapy </span>
   <span class="font10">use </span>
   <span class="font10">weeks </span>
   <span class="font10">which </span>
   <span class="font10">AASLD </span>
   <span class="font10">but </span>
   <span class="font10">cccDNA </span>
   <span class="font10">current </span>
   <span class="font10">effective </span>
   <span class="font10">found </span>
   <span class="font10">future </span>
   <span class="font10">infected </span>
   <span class="font10">needed </span>
   <span class="font10">new </span>
   <span class="font10">rates </span>
   <span class="font10">replication </span>
   <span class="font10">should </span>
   <span class="font10">SVR </span>
   <span class="font10">States, </span>
   <span class="font10">Study </span>
   <span class="font10">This </span>
   <span class="font10">antigen </span>
   <span class="font10">bone </span>
   <span class="font10">direct‐acting </span>
   <span class="font10">high </span>
   <span class="font10">more </span>
   <span class="font10">normal </span>
   <span class="font10">only </span>
   <span class="font10">px; </span>
   <span class="font10">review </span>
   <span class="font10">study </span>
   <span class="font10">through </span>
   <span class="font10">treating </span>
   <span class="font10">work </span>
   <span class="font10">{font-family </span>
   <span class="font10">&amp;lt; </span>
   <span class="font10">Association </span>
   <span class="font10">Disease </span>
   <span class="font10">EASL </span>
   <span class="font10">Gastroenterol </span>
   <span class="font10">Global </span>
   <span class="font10">IU/mL </span>
   <span class="font10">RNA </span>
   <span class="font10">States. </span>
   <span class="font10">U.S. </span>
   <span class="font10">Viral </span>
   <span class="font10">access </span>
   <span class="font10">can </span>
   <span class="font10">clinical </span>
   <span class="font10">estimated </span>
   <span class="font10">following </span>
   <span class="font10">font-size </span>
   <span class="font10">health </span>
   <span class="font10">hepatitis, </span>
   <span class="font10">inhibitors </span>
   <span class="font10">months </span>
   <span class="font10">need </span>
   <span class="font10">regarding </span>
   <span class="font10">regardless </span>
   <span class="font10">reported </span>
   <span class="font10">systematic </span>
   <span class="font10">targeting </span>
   <span class="font10">transplantation </span>
   <span class="font10">treated </span>
   <span class="font10">treatment. </span>
   <span class="font10">was </span>
   <span class="font10">would </span>
   <span class="font10">Although </span>
   <span class="font10">Clin </span>
   <span class="font10">Following </span>
   <span class="font10">Future </span>
   <span class="font10">HBeAg‐positive </span>
   <span class="font10">HCV‐infected </span>
   <span class="font10">Med;:‐. </span>
   <span class="font10">Organization </span>
   <span class="font10">Screening </span>
   <span class="font10">Wiley </span>
   <span class="font10">become </span>
   <span class="font10">compared </span>
   <span class="font10">cure. </span>
   <span class="font10">currently </span>
   <span class="font10">double; </span>
   <span class="font10">drugs </span>
   <span class="font10">duration </span>
   <span class="font10">entry </span>
   <span class="font10">failure </span>
   <span class="font10">fibrosis </span>
   <span class="font10">further </span>
   <span class="font10">hepatocellular </span>
   <span class="font10">history </span>
   <span class="font10">identify </span>
   <span class="font10">include </span>
   <span class="font10">individuals </span>
   <span class="font10">multiple </span>
   <span class="font10">one </span>
   <span class="font10">past </span>
   <span class="font10">patients. </span>
   <span class="font10">phase </span>
   <span class="font10">prior </span>
   <span class="font10">recommended </span>
   <span class="font10">treat </span>
   <span class="font10">treatment, </span>
   <span class="font10">vaccination </span>
   <span class="font10">vaccine </span>
   <span class="font10">well </span>
   <span class="font10">%‐% </span>
   <span class="font10">&amp;amp; </span>
   <span class="font10">(&amp;gt;%), </span>
   <span class="font10">(C) </span>
   <span class="font10">(Table </span>
   <span class="font10">Abbreviations: </span>
   <span class="font10">European </span>
   <span class="font10">Guidance </span>
   <span class="font10">John </span>
   <span class="font10">Ltd, </span>
   <span class="font10">Preventive </span>
   <span class="font10">Services </span>
   <span class="font10">Sons, </span>
   <span class="font10">Table </span>
   <span class="font10">Virus </span>
   <span class="font10">acute </span>
   <span class="font10">adults </span>
   <span class="font10">advanced </span>
   <span class="font10">advances </span>
   <span class="font10">allow </span>
   <span class="font10">also </span>
   <span class="font10">although </span>
   <span class="font10">between </span>
   <span class="font10">bold </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">disease, </span>
   <span class="font10">disoproxil </span>
   <span class="font10">distribution </span>
   <span class="font10">due </span>
   <span class="font10">during </span>
   <span class="font10">endpoints </span>
   <span class="font10">epidemiology </span>
   <span class="font10">experienced </span>
   <span class="font10">function </span>
   <span class="font10">genotype </span>
   <span class="font10">hepatocyte </span>
   <span class="font10">hold </span>
   <span class="font10">increase </span>
   <span class="font10">infection: </span>
   <span class="font10">into </span>
   <span class="font10">key </span>
   <span class="font10">lower </span>
   <span class="font10">made </span>
   <span class="font10">organ </span>
   <span class="font10">over </span>
   <span class="font10">patients, </span>
   <span class="font10">pegylated </span>
   <span class="font10">people </span>
   <span class="font10">potential </span>
   <span class="font10">previous </span>
   <span class="font10">remains </span>
   <span class="font10">research </span>
   <span class="font10">response </span>
   <span class="font10">safety </span>
   <span class="font10">seen </span>
   <span class="font10">sofosbuvir </span>
   <span class="font10">solid; </span>
   <span class="font10">still </span>
   <span class="font10">testing, </span>
   <span class="font10">than </span>
   <span class="font10">therapies. </span>
   <span class="font10">therapy, </span>
   <span class="font10">therapy. </span>
   <span class="font10">treatments </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">‐week </span>
   <span class="font10">−.% </span>
   <span class="font10">AASLD‐IDSA </span>
   <span class="font10">Add </span>
   <span class="font10">ETV </span>
   <span class="font10">For </span>
   <span class="font10">Force </span>
   <span class="font10">Further </span>
   <span class="font10">Guidelines </span>
   <span class="font10">HBeAg‐negative </span>
   <span class="font10">HCV, </span>
   <span class="font10">HIV </span>
   <span class="font10">Infect </span>
   <span class="font10">Infection </span>
   <span class="font10">RBV </span>
   <span class="font10">Recommendations </span>
   <span class="font10">States </span>
   <span class="font10">TDF, </span>
   <span class="font10">Task </span>
   <span class="font10">ULN </span>
   <span class="font10">across </span>
   <span class="font10">aged </span>
   <span class="font10">analysis </span>
   <span class="font10">antibody </span>
   <span class="font10">anticipated </span>
   <span class="font10">approved </span>
   <span class="font10">birth </span>
   <span class="font10">both </span>
   <span class="font10">carcinoma </span>
   <span class="font10">care, </span>
   <span class="font10">cases </span>
   <span class="font10">chronically </span>
   <span class="font10">cirrhosis, </span>
   <span class="font10">closed </span>
   <span class="font10">cohort </span>
   <span class="font10">coinfection </span>
   <span class="font10">cost‐effective </span>
   <span class="font10">courier; </span>
   <span class="font10">covalently </span>
   <span class="font10">data </span>
   <span class="font10">detectable </span>
   <span class="font10">directions </span>
   <span class="font10">efficacy </span>
   <span class="font10">elevated </span>
   <span class="font10">elimination </span>
   <span class="font10">em; </span>
   <span class="font10">even </span>
   <span class="font10">fumarate </span>
   <span class="font10">generally </span>
   <span class="font10">genotypes </span>
   <span class="font10">guidance </span>
   <span class="font10">human </span>
   <span class="font10">identifying </span>
   <span class="font10">immunodeficiency </span>
   <span class="font10">important </span>
   <span class="font10">inhibitor </span>
   <span class="font10">inject </span>
   <span class="font10">large </span>
   <span class="font10">life </span>
   <span class="font10">million </span>
   <span class="font10">nucleos(t)ide </span>
   <span class="font10">optimal </span>
   <span class="font10">oral </span>
   <span class="font10">other </span>
   <span class="font10">persistent </span>
   <span class="font10">pgRNA </span>
   <span class="font10">providers. </span>
   <span class="font10">pt;} </span>
   <span class="font10">public </span>
   <span class="font10">receiving </span>
   <span class="font10">reduced </span>
   <span class="font10">regimen </span>
   <span class="font10">resistance </span>
   <span class="font10">result </span>
   <span class="font10">screen </span>
   <span class="font10">screening, </span>
   <span class="font10">such </span>
   <span class="font10">surface </span>
   <span class="font10">surveillance </span>
   <span class="font10">targets </span>
   <span class="font10">toward </span>
   <span class="font10">trials </span>
   <span class="font10">two </span>
   <span class="font10">under </span>
   <span class="font10">vs. </span>
   <span class="font10">were </span>
   <span class="font10">when </span>
   <span class="font10">worldwide </span>
   <span class="font10">years, </span>
  </p>
 </body>
</html>
